Comparison of netarsudil and latanoprostene bunod as adjuncts to maximum medical therapy in primary open-angle glaucoma

Published:April 11, 2022DOI:



      Compare the efficacy of new agents netarsudil 0.02% (NET) and latanoprostene bunod 0.024% (LB) ophthalmic solutions as adjuncts to traditional 4-class maximum medical therapy (MMT) in primary open angle glaucoma (POAG).


      Single-centre retrospective cohort study using records from a university glaucoma clinic from 2017 to 2021 with follow-up at 30–90 days.


      Patients with POAG already taking 4-class MMT who either added NET (n = 24) or exchanged a currently prescribed prostaglandin analogue (PGA) for LB (n = 11) with no prior surgery except for selective laser trabeculoplasty or cataract extraction >1 year prior.


      Either addition of NET or exchange of PGA for LB and otherwise continuing MMT. Outcome measures were absolute intraocular pressure reduction (IOPR) in mm Hg, percent IOPR, and proportion of patients achieving >10% IOPR.


      Data from 35 eyes in 35 patients were analyzed. Intraocular pressure reduction after adding NET was significantly greater than after exchanging a PGA for LB. Percent IOPR by NET also was significantly greater than after exchanging PGA for LB. The proportion of patients reaching therapeutic threshold after the addition of NET was significantly greater than after exchange of PGA for LB.


      In patients with POAG on MMT, addition of NET was associated with significantly greater magnitude of IOPR and a significantly greater proportion of patients reaching the >10% IOPR threshold compared with exchange of PGA for LB.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zimmerman TJ
        • Fechtner RD.
        Maximal medical therapy for glaucoma.
        Arch Ophthalmol. 1997; 115: 1579-1580
        • Dasso L
        • Al-Khaled T
        • Sonty S
        • Aref AA.
        Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date.
        Clin Ophthalmol. 2018; 12: 1939-1944
        • Kaufman PL.
        Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
        Expert Opin Pharmacother. 2017; 18: 433-444
        • Weinreb RN
        • Liebmann JM
        • Martin KR
        • Kaufman PL
        • Vittitow JL.
        Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings.
        J Glaucoma. 2018; 27: 7-15
        • Gonzalez LE
        • Boylan PM.
        Netarsudil for the treatment of open-angle glaucoma and ocular hypertension: a literature review.
        Ann Pharmacother. 2020; 1060028020971215
        • Budenz DL.
        A clinician's guide to the assessment and management of nonadherence in glaucoma.
        Ophthalmology. 2009; 116: S43-S47
        • Mehta AA
        • Kanu LN
        • Sood-Mendiratta S
        • et al.
        Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.
        Eur J Ophthalmol. 2021; 1120672121998913
        • Zaman F
        • Gieser SC
        • Schwartz GF
        • Swan C
        • Williams JM.
        A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.
        Curr Med Res Opin. 2021; 37: 1011-1020
        • Villegas NC
        • Lee W-S.
        Effectiveness of netarsudil as an additional therapy for glaucoma in patients already on maximally tolerated medical therapy.
        Clin Ophthalmol. 2021; 15: 4367-4372
        • Foot B
        • MacEwen C.
        Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome.
        Eye (Lond). 2017; 31: 771-775
        • Weinreb RN
        • Scassellati Sforzolini B
        • Vittitow J
        • Liebmann J
        Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study.
        Ophthalmology. 2016; 123: 965-973
        • Weinreb RN
        • Ong T
        • Scassellati Sforzolini B
        • et al.
        A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
        Br J Ophthalmol. 2015; 99: 738-745
        • Medeiros FA
        • Martin KR
        • Peace J
        • Scassellati Sforzolini B
        • Vittitow JL
        • Weinreb RN
        Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study.
        Am J Ophthalmol. 2016; 168: 250-259
        • Serle JB
        • Katz LJ
        • McLaurin E
        • et al.
        Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
        Am J Ophthalmol. 2018; 186: 116-127
        • Kahook MY
        • Serle JB
        • Mah FS
        • et al.
        Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
        Am J Ophthalmol. 2019; 200: 130-137
        • Khouri AS
        • Serle JB
        • Bacharach J
        • et al.
        Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study.
        Am J Ophthalmol. 2019; 204: 97-104
        • Hedman K
        • Alm A.
        A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol.
        Eur J Ophthalmol. 2000; 10: 95-104